BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study - Concepedia

Concepedia

Publication | Closed Access

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

72

Citations

0

References

2019

Year

Niharika B. Mettu, Erin Twohy, Fang‐Shu Ou, Þorvarður R. Hálfdánarson, Heinz‐Josef Lenz, Rimini Breakstone, Patrick M. Boland, Oxana Crysler, Christina Wu, Axel Grothey,

Annals of Oncology

No additional data available for this publication yet. Check back later!